Virax Biolabs (VRAX) Cash & Equivalents (2021 - 2026)

Virax Biolabs' Cash & Equivalents history runs 6 years deep, the most recent figure standing at $6.4 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 52.26% year-over-year to $6.4 million; the TTM figure through Mar 2026 stood at $6.4 million (up 52.26% YoY), while the FY2026 annual figure was $6.4 million, up 52.26% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $6.4 million, up from $4.2 million in the prior quarter.
• The five-year high for Cash & Equivalents was $9.4 million in Q1 2023, with the low at $21756.0 in Q1 2022.
• The 5-year median for Cash & Equivalents is $5.3 million (2025), against an average of $5.2 million.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents jumped 42888.32% in 2023, then slumped 61.62% in 2024.
• Virax Biolabs' Cash & Equivalents stood at $21756.0 in 2022, then surged by 42888.32% to $9.4 million in 2023, then declined by 22.1% to $7.3 million in 2024, then sank by 41.96% to $4.2 million in 2025, then jumped by 52.26% to $6.4 million in 2026.
• Business Quant data shows VRAX's Cash & Equivalents at $6.4 million in Q1 2026, $4.2 million in Q1 2025, and $7.3 million in Q3 2024.